JP5329439B2 - サマプリンａの新規の誘導体、その合成方法、及び癌の予防又は治療のためのそれらの使用 - Google Patents

サマプリンａの新規の誘導体、その合成方法、及び癌の予防又は治療のためのそれらの使用 Download PDF

Info

Publication number
JP5329439B2
JP5329439B2 JP2009551288A JP2009551288A JP5329439B2 JP 5329439 B2 JP5329439 B2 JP 5329439B2 JP 2009551288 A JP2009551288 A JP 2009551288A JP 2009551288 A JP2009551288 A JP 2009551288A JP 5329439 B2 JP5329439 B2 JP 5329439B2
Authority
JP
Japan
Prior art keywords
group
cancer
molecule
uvi5008
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009551288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520192A (ja
Inventor
ヒンリッヒ グローネメイヤー
ルチア アルトゥッチ
レラ アンヘル デ
ヘンドリック ヘーラルト ストゥンネンベルフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Strasbourg filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2010520192A publication Critical patent/JP2010520192A/ja
Application granted granted Critical
Publication of JP5329439B2 publication Critical patent/JP5329439B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2009551288A 2007-02-28 2008-02-28 サマプリンａの新規の誘導体、その合成方法、及び癌の予防又は治療のためのそれらの使用 Expired - Fee Related JP5329439B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290253.9 2007-02-28
EP07290253A EP1964835A1 (de) 2007-02-28 2007-02-28 Derivate von Psammaplin A, Verfahren zu ihrer Synthese und ihre Verwendung für die Vorbeugung oder Behandlung von Krebs
PCT/IB2008/001887 WO2008125988A1 (en) 2007-02-28 2008-02-28 Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer

Publications (2)

Publication Number Publication Date
JP2010520192A JP2010520192A (ja) 2010-06-10
JP5329439B2 true JP5329439B2 (ja) 2013-10-30

Family

ID=37998389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009551288A Expired - Fee Related JP5329439B2 (ja) 2007-02-28 2008-02-28 サマプリンａの新規の誘導体、その合成方法、及び癌の予防又は治療のためのそれらの使用

Country Status (10)

Country Link
US (1) US8338473B2 (de)
EP (2) EP1964835A1 (de)
JP (1) JP5329439B2 (de)
CN (1) CN101720315B (de)
AT (1) ATE516270T1 (de)
AU (1) AU2008238924B2 (de)
CA (1) CA2678833A1 (de)
ES (1) ES2372717T3 (de)
IL (1) IL200410A (de)
WO (1) WO2008125988A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
CN102503869B (zh) * 2011-10-19 2014-05-21 沈阳药科大学 2-羟亚胺苯丙酰胺基乙二硫基类衍生物及其应用
EP2730558A1 (de) * 2012-11-08 2014-05-14 Ikerchem, S.L. Indolderivate, pharmazeutische Zusammensetzungen mit solchen Indolen und deren Verwendung als DNA-Methylierungsmodulatoren
EP3207932A1 (de) 2016-02-19 2017-08-23 Universität Stuttgart Dna-methyltransferaseninhibitoren für rett-syndromtherapie
US20210299069A1 (en) * 2016-08-26 2021-09-30 Idogen Ab Psammaplin a for modulating ido expression
CN107739316B (zh) * 2017-11-14 2020-07-14 中国医科大学 一种溴代酪氨酸生物碱类化合物及其制备方法和用途
CN111548286B (zh) * 2020-05-13 2022-09-06 沈阳药科大学 一种具有hdac3抑制活性的psa衍生物及其应用
CN115028567A (zh) * 2022-06-24 2022-09-09 大理大学 一种吲哚生物碱Luteoride B的合成工艺
CN114890932A (zh) * 2022-06-24 2022-08-12 大理大学 一种吲哚生物碱Luteoride A的首次全合成工艺
CN115925675B (zh) * 2022-11-10 2025-04-01 中国海洋大学 一种Psammaplin A类衍生物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643365B2 (en) * 1991-02-28 1993-11-11 Aventisub Ii Inc. NMDA antagonists
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CA2618770A1 (en) * 2005-08-25 2007-03-01 Emory University Hif inhibitors

Also Published As

Publication number Publication date
JP2010520192A (ja) 2010-06-10
AU2008238924B2 (en) 2013-06-27
IL200410A0 (en) 2010-05-31
US8338473B2 (en) 2012-12-25
CA2678833A1 (en) 2008-10-23
EP1964835A1 (de) 2008-09-03
IL200410A (en) 2013-10-31
CN101720315B (zh) 2012-07-18
ATE516270T1 (de) 2011-07-15
CN101720315A (zh) 2010-06-02
EP2137147A1 (de) 2009-12-30
EP2137147B1 (de) 2011-07-13
WO2008125988A1 (en) 2008-10-23
ES2372717T3 (es) 2012-01-25
AU2008238924A1 (en) 2008-10-23
US20100120885A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
JP2010520192A (ja) サマプリンａの新規の誘導体、その合成方法、及び癌の予防又は治療のためのそれらの使用
CN113164495B (zh) E3连接酶的共价靶向
US12514850B2 (en) Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
JP2014512337A (ja) スチルベン類似体およびがんを処置する方法
CN112566898B (zh) 12(s)-脂氧合酶（12-lox）的选择性抑制剂及其使用方法
Baud et al. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
Farag et al. Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes
Zhu et al. Discovery of novel 5-cyano-3-phenylindole-based LSD1/HDAC dual inhibitors for colorectal cancer treatment
ES3028184T3 (en) Substituted heterocycles as c-myc targeting agents
Ding et al. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity
US11059815B2 (en) Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
Parker et al. Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L
KR101624344B1 (ko) 히스톤 탈아세틸화 효소 억제 활성을 갖는 신규한 3-치환-2-옥소인돌린 기반 n-히드록시프로펜아미드 및 이를 유효성분으로 포함하는 항암용 조성물
Kamal et al. Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents
Fathy et al. Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer
KR102023845B1 (ko) 히스톤 탈아세틸효소 억제제 및 이의 용도
TW201429981A (zh) 抗組蛋白去乙醯酶及３－羥－３－甲基戊二輔酶ａ還原酶之雙重作用抑制劑
KR102000035B1 (ko) Hdac 억제제로서 신규한 퀴나졸린 기반 하이드록사민산 또는 n-하이드록시벤즈아마이드 및 이를 유효성분으로 포함하는 항암제 조성물
CN116813620B (zh) 一种基于hsp90蛋白靶向降解gpx4的嵌合体及制备方法和应用
KR20030018800A (ko) 시토크롬 피450 1비1 억제활성을 갖는 페닐환 유도체 및약학적으로 허용가능한 그의 염, 그의 제조방법 및 이를함유하는 조성물
KR20180071889A (ko) 신규한 n-히드록시벤즈아미드 및 이의 용도
KR20180071890A (ko) 신규한 히드록삼산 및 이의 용도
RU2761880C1 (ru) Адамантилсодержащие производные 1,2,4-триазола и 1,3,4-тиадиазола, имеющие монотерпеноидные фрагменты, используемые в качестве ингибиторов фермента тирозил-ДНК-фосфодиэстеразы 1
Bauer Targeting reader domains of the epigenetic code
KR101996871B1 (ko) 히스톤 탈아세틸화 효소 억제 활성을 갖는 신규한 3-치환-2-옥소인돌린 기반 히드록삼산 화합물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130724

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees